Abstract
The risk of venous thromboembolism (VTE) increases in the presence of plasma cell dyscrasias. Monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) share an intrinsic increased risk of VTE. Treatment with thalidomide and lenalidomide further increases the incidence of VTE in certain MM patient subsets. The pathogenesis remains unclear, but probably involves several factors such as activation of procoagulant factors, acquired activated protein C resistance, and inflammation. In addition to general risk factors for VTE, such as older age, immobility, surgery, and inherited thrombophilia, there are some MM-specific and treatment-related factors that contribute to the increased risk. The risk for VTE is high under treatment with thalidomide or lenalidomide in combination with dexamethasone or multi-agent chemotherapy. We report 3 cases of MM with VTE with review of the literature. This review highlights the risk factors for VTE in MM and general, disease-specific and treatment-related mechanisms for thrombosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.